Design, Synthesis, and Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells

被引：31

作者：

Strong, Amy L. ^{[1
]}

Jiang, Quan ^{[2
,3
]}

Zhang, Qiang ^{[2
,3
]}

Zheng, Shilong ^{[2
,3
]}

Boue, Stephen M. ^{[4
]}

Elliott, Steven ^{[5
]}

Burow, Matthew E. ^{[5
]}

Bunnell, Bruce A. ^{[1
]}

Wang, Guangdi ^{[2
,3
]}

机构：

[1] Tulane Univ, Sch Med, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70112 USA

[2] Xavier Univ, Dept Chem, New Orleans, LA 70125 USA

[3] Xavier Univ, RCMI Canc Res Program, New Orleans, LA 70125 USA

[4] USDA, So Reg Res Ctr, New Orleans, LA 70130 USA

[5] Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2014年 / 5卷 / 02期

关键词：

Daidzein analogs; mesenchymal stem cells; BMSCs; osteogenesis; BONE LOSS; PHYTOESTROGENS; OSTEOPOROSIS; PATHOGENESIS; GENISTEIN; RATS;

D O I：

10.1021/ml400397k

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Osteoporosis is caused by an overstimulation of osteoclast activity and the destruction of the bone extracellular matrix. Without the normal architecture, osteoblast cells are unable to rebuild phenotypically normal bone. Hormone replacement therapy with estrogen has been effective in increasing osteoblast activity but also has resulted in the increased incidence of breast and uterine cancer. In this study we designed and synthesized a series of daidzein analogs to investigate their osteogenic induction potentials. Human bone marrow derived mesenchymal stem cells (MSCs) from three different donors were treated with daidzein analogs and demonstrated enhanced osteogenesis when compared to daidzein treatment. The enhanced osteogenic potential of these daidzein analogs resulted in increased osterix (Sp7), alkaline phosphatase (ALP), osteopontin (OPN), and insulin-like growth factor 1 (IGF-1), which are osteogenic transcription factors that regulate the maturation of osteogenic progenitor cells into mature osteoblast cells.

引用

页码：143 / 148

页数：6

共 23 条

[1] THE ECONOMIC AND HUMAN COSTS OF OSTEOPOROTIC FRACTURE [J].

BARRETTCONNOR, E .

AMERICAN JOURNAL OF MEDICINE, 1995, 98 :S3-S8

[2] Continuing Bisphosphonate Treatment for Osteoporosis - For Whom and for How Long? [J].

Black, Dennis M. ;

Bauer, Douglas C. ;

Schwartz, Ann V. ;

Cummings, Steven R. ;

Rosen, Clifford J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (22) :2051-2053

[3]

Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]

[4]

Cho Y, 2002, J NUTR, V132, p614S

[5] Summary of meta-analyses of therapies for postmenopausal osteoporosis [J].

Cranney, A ;

Guyatt, G ;

Griffith, L ;

Wells, G ;

Tugwell, P ;

Rosen, C .

ENDOCRINE REVIEWS, 2002, 23 (04) :570-578

[6]

Cusack S. J. C., 2001, ANN NUTR METAB, V45

[7] Dose-dependent effects of phytoestrogens on bone [J].

Dang, ZC ;

Lowik, C .

TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2005, 16 (05) :207-213

[8]

De Wilde A. C. C., 2001, ANN NUTR METAB, V45

[9] The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats [J].

Fanti, P ;

Monier-Faugere, MC ;

Geng, Z ;

Schmidt, J ;

Morris, PE ;

Cohen, D ;

Malluche, HH .

OSTEOPOROSIS INTERNATIONAL, 1998, 8 (03) :274-281

[10]

Foundation NO., 2002, Americas bone health: the state of osteoporosis and low bone mass in our nation, P1

← 1 2 3 →